EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 180 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 2.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $997,122 | -20.2% | 63,229 | -1.6% | 0.00% | – |
| Q2 2023 | $1,248,768 | -61.2% | 64,237 | -43.4% | 0.00% | -100.0% |
| Q1 2023 | $3,217,528 | -8.1% | 113,413 | -5.3% | 0.00% | 0.0% |
| Q4 2022 | $3,500,000 | +24.6% | 119,740 | +12.6% | 0.00% | 0.0% |
| Q3 2022 | $2,810,000 | -38.3% | 106,317 | +3.7% | 0.00% | 0.0% |
| Q2 2022 | $4,555,000 | -20.6% | 102,524 | -11.5% | 0.00% | 0.0% |
| Q1 2022 | $5,735,000 | -9.6% | 115,869 | -7.0% | 0.00% | 0.0% |
| Q4 2021 | $6,347,000 | -9.4% | 124,649 | -0.7% | 0.00% | 0.0% |
| Q3 2021 | $7,005,000 | +42.2% | 125,572 | +9.1% | 0.00% | 0.0% |
| Q2 2021 | $4,926,000 | -1.7% | 115,095 | -4.1% | 0.00% | 0.0% |
| Q1 2021 | $5,010,000 | -16.2% | 120,059 | -6.4% | 0.00% | 0.0% |
| Q4 2020 | $5,976,000 | +8.4% | 128,302 | -1.1% | 0.00% | 0.0% |
| Q3 2020 | $5,511,000 | +1.4% | 129,721 | +14.5% | 0.00% | 0.0% |
| Q2 2020 | $5,434,000 | +7.6% | 113,255 | +3.1% | 0.00% | -50.0% |
| Q1 2020 | $5,050,000 | -28.1% | 109,811 | -6.1% | 0.00% | 0.0% |
| Q4 2019 | $7,026,000 | +0.7% | 116,939 | -5.2% | 0.00% | 0.0% |
| Q3 2019 | $6,979,000 | -2.6% | 123,354 | -4.2% | 0.00% | 0.0% |
| Q2 2019 | $7,167,000 | +6.7% | 128,714 | -3.2% | 0.00% | 0.0% |
| Q1 2019 | $6,715,000 | +21.5% | 132,975 | -3.1% | 0.00% | 0.0% |
| Q4 2018 | $5,527,000 | -55.1% | 137,184 | -22.8% | 0.00% | -33.3% |
| Q3 2018 | $12,314,000 | +5.9% | 177,619 | +15.6% | 0.00% | 0.0% |
| Q2 2018 | $11,630,000 | +49.8% | 153,716 | +4.3% | 0.00% | +50.0% |
| Q1 2018 | $7,766,000 | -6.2% | 147,406 | -4.8% | 0.00% | 0.0% |
| Q4 2017 | $8,275,000 | +3.3% | 154,885 | +15.3% | 0.00% | 0.0% |
| Q3 2017 | $8,008,000 | -12.9% | 134,277 | +15.2% | 0.00% | -33.3% |
| Q2 2017 | $9,191,000 | -4.5% | 116,510 | +0.4% | 0.00% | 0.0% |
| Q1 2017 | $9,622,000 | +4.0% | 116,028 | -0.5% | 0.00% | 0.0% |
| Q4 2016 | $9,251,000 | +41.7% | 116,608 | +25.0% | 0.00% | +50.0% |
| Q3 2016 | $6,529,000 | +305.3% | 93,265 | +124.5% | 0.00% | – |
| Q2 2016 | $1,611,000 | -2.7% | 41,540 | +1.6% | 0.00% | -100.0% |
| Q1 2016 | $1,656,000 | -69.9% | 40,882 | -34.2% | 0.00% | -50.0% |
| Q4 2015 | $5,508,000 | +20.6% | 62,112 | +0.7% | 0.00% | +100.0% |
| Q3 2015 | $4,566,000 | -15.1% | 61,675 | -7.3% | 0.00% | 0.0% |
| Q2 2015 | $5,379,000 | +310.3% | 66,534 | +112.7% | 0.00% | – |
| Q1 2015 | $1,311,000 | – | 31,276 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |